Exploratory, Interventional, Open-label, Fixed-dose Study With Selincro As-needed Use, in Alcohol Dependent Patients With Liver Impairment
Phase of Trial: Phase IV
Latest Information Update: 04 Mar 2016
Price : $35 *
At a glance
- Drugs Nalmefene (Primary)
- Indications Alcohol withdrawal
- Focus Adverse reactions; Therapeutic Use
- Sponsors Lundbeck A/S
- 31 Aug 2018 Biomarkers information updated
- 19 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrils.gov.
- 05 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrils.gov.